{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:16:12Z","timestamp":1769206572674,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T00:00:00Z","timestamp":1376524800000},"content-version":"vor","delay-in-days":348,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY012509"],"award-info":[{"award-number":["EY012509"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 97806"],"award-info":[{"award-number":["MOP 97806"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["IAO 77736"],"award-info":[{"award-number":["IAO 77736"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ajpath.2012.05.036","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T00:09:47Z","timestamp":1345075787000},"page":"866-874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A Novel Function of p53"],"prefix":"10.1016","volume":"181","author":[{"given":"Hetian","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Andre","family":"Rheaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Maberley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif","family":"Samad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrius","family":"Kazlauskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2012.05.036_bib1","first-page":"2315","article-title":"Proliferative Vitreoretinopathy","author":"Han","year":"2008"},{"key":"10.1016\/j.ajpath.2012.05.036_bib2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/0002-9394(82)90013-7","article-title":"The incidence of retinal detachment in Rochester, Minnesota, 1970\u20131978","volume":"94","author":"Wilkes","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archopht.1982.01030030291012","article-title":"Epidemiology of retinal detachment","volume":"100","author":"Haimann","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/bjo.82.2.106","article-title":"Growth factors in proliferative vitreoretinopathy","volume":"82","author":"Charteris","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib5","first-page":"669","article-title":"Retinal Detachment","author":"Michels","year":"1990"},{"key":"10.1016\/j.ajpath.2012.05.036_bib6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bjo.79.10.874","article-title":"Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases","volume":"79","author":"Mietz","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00006982-199414050-00005","article-title":"Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery","volume":"14","author":"Girard","year":"1994","journal-title":"Retina"},{"key":"10.1016\/j.ajpath.2012.05.036_bib8","first-page":"741","article-title":"[Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery] Spanish","volume":"75","author":"Lle\u00f3 P\u00e9rez","year":"2000","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00006982-199111020-00002","article-title":"Comparative study of clinical factors that predispose patients to proliferative vitreoretinopathy in aphakia","volume":"11","author":"Nagasaki","year":"1991","journal-title":"Retina"},{"key":"10.1016\/j.ajpath.2012.05.036_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/02713680490904142","article-title":"Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy","volume":"30","author":"Rodriguez de la Rua","year":"2005","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajpath.2012.05.036_bib11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.ajo.2004.02.008","article-title":"Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery","volume":"137","author":"Tseng","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006982-198909020-00004","article-title":"Comparative study of clinical factors predisposing patients to proliferative vitreoretinopathy","volume":"9","author":"Yoshino","year":"1989","journal-title":"Retina"},{"key":"10.1016\/j.ajpath.2012.05.036_bib13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","article-title":"Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial","volume":"126","author":"Wiedemann","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib14","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajpath.2012.05.036_bib15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archopht.125.9.1161","article-title":"Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy","volume":"125","author":"Schiff","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib16","article-title":"Pathogenic Mechanisms of Retinal Detachment","author":"Oh","year":"2006"},{"key":"10.1016\/j.ajpath.2012.05.036_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-02598-0.50137-3","article-title":"The Pathogenesis of Proliferative Vitreoretinopathy","author":"Campochiaro","year":"2006"},{"key":"10.1016\/j.ajpath.2012.05.036_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/archopht.1997.01100150239014","article-title":"Mechanisms in ophthalmic disease: pathogenic mechanisms in proliferative vitreoretinopathy","volume":"115","author":"Campochiaro","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0002-9394(14)77054-0","article-title":"Immunohistologic study of epiretinal membranes in proliferative vitreoretinopathy","volume":"110","author":"Baudouin","year":"1990","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib20","first-page":"14","article-title":"Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes","volume":"31","author":"Vinores","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib21","first-page":"2683","article-title":"Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy","volume":"40","author":"Andrews","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib22","first-page":"3649","article-title":"Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases","volume":"35","author":"Robbins","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.exer.2008.10.020","article-title":"PDGF receptors are activated in human epiretinal membranes","volume":"88","author":"Cui","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajpath.2012.05.036_bib24","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1074\/jbc.M808426200","article-title":"Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species\/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells","volume":"284","author":"Lei","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2012.05.036_bib25","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1167\/iovs.08-3042","article-title":"Growth factors outside the PDGF family drive experimental PVR","volume":"50","author":"Lei","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib26","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1128\/MCB.01321-10","article-title":"Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53","volume":"31","author":"Lei","year":"2011","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2012.05.036_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-230X(08)60785-X","article-title":"p53 and human cancer: the first ten thousand mutations","volume":"77","author":"Hainaut","year":"2000","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.ajpath.2012.05.036_bib29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2012.05.036_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0092-8674(00)81774-2","article-title":"Signaling to p53: breaking the MDM2-p53 circuit","volume":"95","author":"Prives","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2012.05.036_bib31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.molcel.2008.08.031","article-title":"Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26","volume":"32","author":"Ofir-Rosenfeld","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.ajpath.2012.05.036_bib32","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm.2392","article-title":"Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11","volume":"17","author":"Sasaki","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2012.05.036_bib33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2174\/138161211795222586","article-title":"Recent advances in the therapeutic perspectives of Nutlin-3","volume":"17","author":"Secchiero","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ajpath.2012.05.036_bib34","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1158\/0008-5472.CAN-11-0058","article-title":"Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a","volume":"71","author":"Brennan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.05.036_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2353\/ajpath.2010.090604","article-title":"N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy","volume":"177","author":"Lei","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib36","doi-asserted-by":"crossref","first-page":"28335","DOI":"10.1074\/jbc.274.40.28335","article-title":"Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis","volume":"274","author":"Rosenkranz","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2012.05.036_bib37","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1167\/iovs.06-0965","article-title":"A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy","volume":"48","author":"Lei","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib38","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.ajpath.2011.08.043","article-title":"A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy","volume":"179","author":"Pennock","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0008-4182(02)80112-0","article-title":"Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells","volume":"37","author":"Wong","year":"2002","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib40","first-page":"2406","article-title":"An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor","volume":"43","author":"Ikuno","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib41","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0002-9394(14)77369-6","article-title":"A comparison of different cellular inocula in an experimental model of massive periretinal proliferation","volume":"93","author":"Fastenberg","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ncb1101-973","article-title":"HER-2\/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation","volume":"3","author":"Zhou","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib43","doi-asserted-by":"crossref","first-page":"21843","DOI":"10.1074\/jbc.M109745200","article-title":"Akt enhances Mdm2-mediated ubiquitination and degradation of p53","volume":"277","author":"Ogawara","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2012.05.036_bib44","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/sj.onc.1205181","article-title":"Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis","volume":"21","author":"Gottlieb","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2012.05.036_bib45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2012.05.036_bib46","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2012.05.036_bib47","first-page":"3107","article-title":"Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor","volume":"41","author":"Ikuno","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib48","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.exer.2009.11.003","article-title":"Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy","volume":"90","author":"Lei","year":"2010","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajpath.2012.05.036_bib49","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1128\/MCB.01967-06","article-title":"Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest","volume":"27","author":"Giono","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib50","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1128\/MCB.23.2.462-473.2003","article-title":"Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation","volume":"23","author":"Mendrysa","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1101\/gad.1378506","article-title":"Tumor suppression and normal aging in mice with constitutively high p53 activity","volume":"20","author":"Mendrysa","year":"2006","journal-title":"Genes Dev"},{"key":"10.1016\/j.ajpath.2012.05.036_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cell.2010.05.031","article-title":"Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells","volume":"142","author":"Loewer","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2012.05.036_bib53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0002-9394(14)77370-2","article-title":"The role of cellular proliferation in an experimental model of massive periretinal proliferation","volume":"93","author":"Fastenberg","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajpath.2012.05.036_bib54","first-page":"629","article-title":"Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein","volume":"7","author":"Iotsova","year":"1996","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.ajpath.2012.05.036_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11010-011-0882-6","article-title":"Id1-induced inhibition of p53 facilitates endothelial cell migration and tube formation by regulating the expression of beta1-integrin","volume":"357","author":"Qiu","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.ajpath.2012.05.036_bib56","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1167\/iovs.08-3315","article-title":"Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2)","volume":"50","author":"Morales","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib57","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.exer.2007.08.014","article-title":"Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway","volume":"85","author":"Morales","year":"2007","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajpath.2012.05.036_bib58","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1167\/iovs.07-1598","article-title":"FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction","volume":"50","author":"Morales","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib59","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1167\/iovs.10-6139","article-title":"Rewiring integrin-mediated signaling and cellular response with the peripheral myelin protein 22 and epithelial membrane protein 2 components of the tetraspan web","volume":"52","author":"Morales","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2012.05.036_bib60","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3109\/02713683.2011.561468","article-title":"Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR)","volume":"36","author":"Telander","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajpath.2012.05.036_bib61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/351453a0","article-title":"The p53 tumour suppressor gene","volume":"351","author":"Levine","year":"1991","journal-title":"Nature"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944012004452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944012004452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T14:38:54Z","timestamp":1757601534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944012004452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0002944012004452"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2012.05.036","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel Function of p53","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2012.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}